Oncolytic virus - CZ BioMed Corp

Drug Profile

Oncolytic virus - CZ BioMed Corp

Alternative Names: BRVLYSIN; CERVLYSIN; CORVLYSIN; HERVLYSIN; LURVLYSIN; MERVLYSIN; OVARVLYSIN; PANRVLYSIN; PRORVLYSIN; RVLYSIN

Latest Information Update: 24 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CZ BioMed Corp
  • Class Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Interferon stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Prostate cancer
  • Preclinical Breast cancer; Cervical cancer; Colorectal cancer; Liver cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer
  • Discontinued Solid tumours

Most Recent Events

  • 24 Jul 2017 CZ Biomed has patent protection for oncolytic virus in USA, Europe, China and Japan (CZ Biomed pipeline, July 2017)
  • 24 Jul 2017 Discontinued - Preclinical for Solid tumours in USA (IV)
  • 24 Jul 2017 Preclinical trials in Breast cancer in USA (IV) (CZ Biomed pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top